Clinical Study of MNC-168 Enteric-coated Capsule in the Treatment of Advanced Intestinal Solid Tumor

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 28, 2022

Primary Completion Date

July 1, 2024

Study Completion Date

July 4, 2024

Conditions
Advanced Malignant Solid Tumors
Interventions
DRUG

Treatment of MNC-168 enteric-coated capsules as a single oral drug

Treatment of live bacterium MNC-168 as a single oral agent as a single oral drug in subjects with advanced malignant solid tumors. First, live fungi can directly or indirectly inhibit tumor growth or induce tumor cell apoptosis through their metabolites or surface proteins, and can also regulate the immune system, especially the tumor microenvironment, to play an antitumor function. Second, tumor immunotherapies exhibit different response levels in different populations, and live bacterial analogs derived from gut microbes may enhance the response to immunotherapy in weakly responding patients.

Trial Locations (1)

Unknown

Guangdong Provincial People's Hospital, Guangzhou

All Listed Sponsors
lead

Moon (Guangzhou) Biotechnology Co., Ltd.

INDUSTRY